Motley Fool Asset Management’s BioMarin Pharmaceuticals BMRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $3.57M | Buy |
65,035
+51,682
| +387% | +$2.84M | 0.16% | 111 |
|
|
2025
Q1 | $944K | Buy |
13,353
+41
| +0.3% | +$2.9K | 0.05% | 161 |
|
|
2024
Q4 | $875K | Sell |
13,312
-135,486
| -91% | -$8.91M | 0.05% | 160 |
|
|
2024
Q3 | $10.4M | Sell |
148,798
-1,941
| -1% | -$136K | 0.62% | 41 |
|
|
2024
Q2 | $12.4M | Buy |
150,739
+103,824
| +221% | +$8.53M | 0.82% | 29 |
|
|
2024
Q1 | $4.1M | Buy |
46,915
+2,792
| +6% | +$244K | 0.27% | 81 |
|
|
2023
Q4 | $4.25M | Sell |
44,123
-1,238
| -3% | -$119K | 0.32% | 74 |
|
|
2023
Q3 | $4.01M | Buy |
45,361
+41,929
| +1,222% | +$3.71M | 0.32% | 70 |
|
|
2023
Q2 | $297K | Buy |
+3,432
| New | +$297K | 0.03% | 188 |
|
|
2023
Q1 | – | Sell |
-3,369
| Closed | -$349K | – | 122 |
|
|
2022
Q4 | $349K | Sell |
3,369
-271
| -7% | -$28K | 0.04% | 178 |
|
|
2022
Q3 | $309K | Sell |
3,640
-84
| -2% | -$7.13K | 0.03% | 187 |
|
|
2022
Q2 | $322K | Buy |
3,724
+13
| +0.4% | +$1.12K | 0.03% | 189 |
|
|
2022
Q1 | $286K | Buy |
3,711
+3,625
| +4,215% | +$279K | 0.02% | 198 |
|
|
2021
Q4 | $8K | Buy |
+86
| New | +$8K | ﹤0.01% | 195 |
|
|
2020
Q3 | – | Sell |
-3,172
| Closed | -$391K | – | 165 |
|
|
2020
Q2 | $391K | Buy |
3,172
+120
| +4% | +$14.8K | 0.04% | 154 |
|
|
2020
Q1 | $258K | Buy |
+3,052
| New | +$258K | 0.03% | 158 |
|
|
2019
Q2 | – | Sell |
-2,827
| Closed | -$251K | – | 170 |
|
|
2019
Q1 | $251K | Buy |
+2,827
| New | +$251K | 0.03% | 160 |
|
|
2018
Q4 | – | Sell |
-2,233
| Closed | -$217K | – | 161 |
|
|
2018
Q3 | $217K | Buy |
+2,233
| New | +$217K | 0.03% | 146 |
|